Novo Nordisk's obesity medication, Wegovy, has shown greater weight loss in women with heart disease compared to men. The study data was presented at the American Diabetes Association’s scientific meeting. The Centers for Medicare and Medicaid Services (CMS) is reviewing the inclusion of Wegovy in its coverage for heart disease patients with obesity. Goldman Sachs analysts have re-rated Novo Nordisk, expecting significant growth in the weight-loss drug market.